Results 201 to 210 of about 116,902 (309)

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer. [PDF]

Curr Treat Options Oncol
Weiner-Gorzel K, McSorley L, Walshe JM.
europepmc   +1 more source

Optimized SPE‐HPLC‐FLD Method for the Simultaneous Determination of Olaparib, Propranolol, and Furosemide in Human Urine

Biomedical Chromatography, Volume 40, Issue 8, August 2026.
ABSTRACT Olaparib belongs to the PARP inhibitors and is widely used as an anticancer drug. Due to frequent side effects, it is usually co‐administered with an antihypertensive, such as propranolol and/or an antidiuretic, such as furosemide. In this study, a highly sensitive HPLC‐FLD method was developed for the simultaneous determination of the three ...
Georgios Kamaris, Antonia Kalagia, Catherine K. Markopoulou   +2 more
wiley   +1 more source

Mitochondrial superoxide sustains a senescence-like phenotype in PARP- inhibited ovarian cancer cells by stabilizing HIF1α. [PDF]

Redox Biol
Yang T, Bu W, Xue X, Wu X, Zhou Y, Chen Y, Li Y, Zhang J, Li P, Shen F, Shi Y, Shao C.   +11 more
europepmc   +1 more source

Treatment patterns and clinical outcomes in real‐world patients with small‐cell lung cancer in South Korea: A single‐center experience

International Journal of Cancer, Volume 159, Issue 3, Page 719-728, 1 August 2026.
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park, Danbee Kang, Jin Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Hojoon Lee, Hyuna Lim, Xerxes Pundole, Juhee Cho, Myung‐Ju Ahn   +11 more
wiley   +1 more source

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer. [PDF]

Biomedicines
Correa Gonzalez B, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, McPherson JD, Li H, Parikh M, Dall'Era M, Gao AC, Lombard AP.   +11 more
europepmc   +1 more source

Beyond Tradition: An Integrated Toxicological, Ecological, and Public Health Perspective on Aristolochic Acids

Journal of Applied Toxicology, Volume 46, Issue 8, Page 2599-2622, August 2026.
ABSTRACT Aristolochia species have long been used in traditional medicine for their presumed anti‐inflammatory, analgesic and antimicrobial properties. However, extensive toxicological and epidemiological evidence now demonstrates that these plants contain aristolochic acids (AAs) I and II, highly potent nephrotoxic, genotoxic, and carcinogenic ...
Victor Ventura de Souza, Lara Rodrigues De Andrade, Tatiana da Silva Souza   +2 more
wiley   +1 more source

From Germline Susceptibility to Therapeutic Vulnerability: DNA Damage Response Gene Mutations Driving Multiple Myeloma Evolution and Precision Therapy. [PDF]

Hum Mutat
Shen Q, Wang Y, Cai L, Qian J.
europepmc   +1 more source

The metalloproteinase ADAM17 promotes acute lung inflammatory responses during pancreatitis

British Journal of Pharmacology, Volume 183, Issue 15, Page 4126-4144, August 2026.
Background and Purpose Acute pancreatitis (AP) is a multifactorial upper gastrointestinal inflammatory disorder that in severe cases (~20% of all AP) is associated with substantial morbidity and mortality, the latter coincident with multiorgan dysfunction, particularly acute lung injury (ALI).
Shermin Chan, Karen Hon, Ruby E. Dawson, Teresa Weng, Jelena Solujic, Yu C. J. Chey, James D. Zuiani, Griffith B. Perkins, P. Toby Coates, Chris Drogemuller, Eddie Sanderlin, Lulu Huang, John Finnie, Stefan Rose‐John, Arash Badiei, Phan Nguyen, Brendan J. Jenkins, Mohamed I. Saad   +17 more
wiley   +1 more source

The role of NAD⁺ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities. [PDF]

Front Oncol
Ma Z, Gong X, Liu F.
europepmc   +1 more source